The United Kingdom and the United States have hammered out a landmark bilateral deal that will guarantee no tariffs on UK medicine exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise spending on medicines through the NHS. This move secures that tariffs on these crucial products will stay at nothing for a duration of 36 months.
This agreement comes after earlier warnings to significantly raise import taxes on patented pharmaceutical products, with figures floated reaching double the cost.
"This arrangement with the United Kingdom bolsters the global environment for new treatments and brings long-overdue fairness to American-British medicine commerce," a statement said.
Economic Impact
Drugs constitute one of the the United Kingdom's largest exports to the US, which is easily the biggest market for major UK drugmakers.
Export figures show that in the 12 months leading up to last September, the UK exported drugs worth billions to the US. This amount accounted for nearly one-fifth of all goods exports in that period.
"This agreement protects jobs, increases funding and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement includes several notable changes from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to increase overall public funding on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Previously, rebates were more than twenty percent.
Recent Tensions
This agreement takes place against a protracted dispute between the drug companies and the ministers over medicine costs and NHS adoption.
The disagreement were intensified by arguments that US customers were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
